CardioGenics Holdings Inc. is focused on technology and products targeting the immunoassay segment of the In-Vitro Diagnostic testing market. The Company has developed the QL Care Analyzer, a point-of-care immuno-analyzer, which is capable of running approximately 200+immunoassay diagnostic tests, such as cardiovascular diagnostic tests. As part of its technology, the Company has also developed a method for silver coating paramagnetic microspheres (a fundamental platform component of immunoassay equipment), which improves instrument sensitivity to light.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

Quotes

Date	Price	Change	Volume

Delayed Quote OTC Markets

More quotes

Market Closed - OTC Markets Other stock markets 18:42:31 24/06/2026 +04			5-day change	1st Jan Change
0.000001 ^USD	-.--%		-.--%	-

10/09/21	Cardiogenics Holdings Inc Announces A Record Date Change for Its Dividend Distribution	CI
04/09/21	CardioGenics Holdings Inc. Announces License Agreement	CI

Market Cap	382K 334K 308K 284K 535K 36.8M 547K 3.68M 1.45M 18.03M 1.44M 1.4M 62.05M	P/E 2014	-2.3x	P/E 2015	-2.17x
Enterprise Value	539K 471K 434K 400K 755K 51.88M 771K 5.19M 2.04M 25.41M 2.02M 1.98M 87.46M	EV / Sales 2014	-	EV / Sales 2015	-
Free-Float	97.49%	Yield 2014 *	-	Yield 2015	-

10/09/21	Cardiogenics Holdings Inc Announces A Record Date Change for Its Dividend Distribution	CI
04/09/21	CardioGenics Holdings Inc. Announces License Agreement	CI
02/11/15	CardioGenics Holdings Inc completed the acquisition of substantially all of the assets of Plasticap Inc.	CI
05/10/15	CardioGenics Holdings Inc entered into a non-binding letter of intent to acquire substantially all of the assets of Plasticap Inc.	CI
13/01/15	CardioGenics Holdings Inc. Appoints Karim Murabet as Director	CI
27/09/13	CardioGenics Holdings Inc Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2013	CI
21/08/13	CardioGenics Holdings Inc Announces Commencement of Beta-Site Testing	CI
05/06/13	CardioGenics Holdings Inc Announces Internal Review Board Approval for Beta-Site Testing	CI
03/06/13	CardioGenics Holdings Inc announced that it has received $0.66 million in funding.	CI
31/05/13	CardioGenics Holdings Inc announced that it expects to receive $1.5 million in funding.	CI
01/03/13	CardioGenics Holdings Inc. Announces Demise of Director, Alexander D. G. Reid	CI
27/02/13	CardioGenics Holdings Inc. announced that it expects to receive $1 million in funding.	CI
17/04/12	CardioGenics Holdings Inc has Changed its Ticker to CGNH from CGNHE	CI

29/09/21	UPDATED: CARDIOGENICS HOLDINGS INC. ANNOUNCES A RECORD DATE CHANGE FOR ITS DIVIDEND DISTRIBUTION	AQ
10/09/21	CARDIOGENICS : ANNOUNCES A RECORD DATE CHANGE FOR ITS DIVIDEND DISTRIBUTION	AQ
04/09/21	CARDIOGENICS : ANNOUNCES LICENSE AGREEMENT AND DIVIDEND DISTRIBUTION	AQ
04/11/15	CardioGenics : Enters Into Asset Purchase Agreement to Acquire All Assets of Ontario-Based Plasticap	MW
05/10/15	CardioGenics : Enters Into Binding Letter of Intent to Acquire Assets of Ontario-Based Plasticap	MW

CardioGenics Holdings Inc Stock

Stocks

CGNH

US14160X2036

Medical Equipment, Supplies & Distribution

Valuation: CardioGenics Holdings Inc

Chart: CardioGenics Holdings Inc

Latest news : CardioGenics Holdings Inc

Press Releases: CardioGenics Holdings Inc

Course Extremes

Managers and Directors: CardioGenics Holdings Inc

Diagnostic & Testing Substances

Financials

Company Profile

Quotes

Manager	Title	Age	Since
Yahia A. Gawad CEO	Chief Executive Officer	68	27/10/2009
James A. Essex DFI	Director of Finance/CFO	78	16/06/2010
Linda J. Sterling IRC	Investor Relations Contact	65	-

Director	Title	Age	Since
Yahia A. Gawad BRD	Director/Board Member	68	06/04/2011
Julian Neil Tabatznik CHM	Chairman	76	16/06/2010
Linda J. Sterling BRD	Director/Board Member	65	16/06/2010

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CARDIOGENICS HOLDINGS INC	-.--%	-.--%	-	-	142
GUARDANT HEALTH, INC.	+0.56%	-2.61%	+235.49%	+310.94%	20.67B
BIOMÉRIEUX	-0.82%	+2.26%	-38.81%	-22.84%	9.85B
LANTHEUS HOLDINGS, INC.	+2.36%	+1.85%	+53.31%	+20.60%	7B
10X GENOMICS, INC.	-1.66%	+2.36%	+260.00%	-27.26%	5.55B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	+0.36%	+3.63%	-17.20%	-23.46%	5.23B
ANDON HEALTH CO., LTD.	+10.00%	+34.69%	+101.94%	+124.62%	4.9B
CARIS LIFE SCIENCES, INC.	+0.06%	-2.94%	-45.38%	-	4.66B
DIASORIN S.P.A.	+1.07%	+0.83%	-21.28%	-24.99%	4.2B
AUTOBIO DIAGNOSTICS CO., LTD.	-2.66%	+4.71%	-15.83%	-39.84%	2.72B
Average	+0.93%	+5.25%	+56.92%	+39.72%	6.48B
Weighted average by Cap.	+0.93%	+3.67%	+98.27%	+107.57%

	2014	2015
Net sales	-	-
Net income	-2.68M -2.34M -2.16M -1.99M -3.75M -258M -3.84M -25.83M -10.16M -126M -10.06M -9.84M -435M	-1.92M -1.67M -1.55M -1.42M -2.68M -185M -2.74M -18.47M -7.26M -90.38M -7.2M -7.04M -311M
Net Debt	132K 116K 107K 98.29K 185K 12.73M 189K 1.27M 501K 6.24M 497K 486K 21.47M	157K 137K 126K 116K 219K 15.07M 224K 1.51M 593K 7.38M 588K 575K 25.41M

Current year	0		0
1 year	0		0
3 years	0		0
5 years	0		0.11
10 years	0		0.29